Patents by Inventor Raymond Gilmour

Raymond Gilmour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR
    Publication number: 20230146387
    Abstract: The present invention relates to combination therapy with (a) a mutant IDH inhibitor having the Formula I and (b) one or more of an antimetabolite agent, a hypomethylating agent, and a mutant Flt3 (Flt3) inhibitor, for the treatment of cancer.
    Type: Application
    Filed: March 22, 2021
    Publication date: May 11, 2023
    Inventors: Nathan Arthur BROOKS, Raymond GILMOUR
  • COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR AND A BCL-2 INHIBITOR
    Publication number: 20230135992
    Abstract: The present invention relates to combination therapy with a mutant IDH inhibitor of Formula (I) and a Bcl-2 inhibitor, for the treatment of cancer.
    Type: Application
    Filed: March 22, 2021
    Publication date: May 4, 2023
    Inventors: Nathan Arthur BROOKS, Courtney DINARDO, Raymond GILMOUR, Marina KONOPLEVA, Vivian SALAMA
  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
    Patent number: 11629156
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: April 18, 2023
    Assignee: Eli Lilly and Company
    Inventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Raymond Gilmour, Patric James Hahn, Zoran Rankovic
  • METHOD FOR TREATING IDH1 INHIBITOR-RESISTANT SUBJECTS
    Publication number: 20230071978
    Abstract: The present invention relates to the treatment of human cancer subjects with a mutant isocitrate dehydrogenase 1 inhibitor of formula I.
    Type: Application
    Filed: March 22, 2021
    Publication date: March 9, 2023
    Inventors: Nathan Arthur BROOKS, Raymond GILMOUR
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
    Publication number: 20210230185
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Application
    Filed: March 16, 2021
    Publication date: July 29, 2021
    Inventors: Renato Alejandro BAUER, Serge Louis BOULET, Timothy Paul BURKHOLDER, Raymond GILMOUR, Patric James HAHN, Zoran RANKOVIC
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
    Publication number: 20210206780
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Application
    Filed: March 16, 2021
    Publication date: July 8, 2021
    Inventors: Renato Alejandro BAUER, Serge Louis BOULET, Timothy Paul BURKHOLDER, Raymond GILMOUR, Patric James HAHN, Zoran RANKOVIC
  • Mutant IDH1 inhibitors
    Patent number: 10696665
    Abstract: The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 30, 2020
    Assignee: Eli Lilly and Company
    Inventors: Wenceslao Lumeras Amador, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, Raymond Gilmour, Patric James Hahn, Renato Alejandro Bauer, Zoran Rankovic
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
    Publication number: 20200079791
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Application
    Filed: December 8, 2017
    Publication date: March 12, 2020
    Inventors: Renato Alejandro BAUER, Serge Louis BOULET, Timothy Paul BURKHOLDER, Raymond GILMOUR, Patric James HAHN, Zoran RANKOVIC
  • MUTANT IDH1 INHIBITORS
    Publication number: 20190292175
    Abstract: The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 26, 2019
    Inventors: Wenceslao LUMERAS AMADOR, Serge Louis BOULET, Timothy Paul BURKHOLDER, Santiago CARBALLARES MARTIN, Raymond GILMOUR, Patric James HAHN, Renato Alejandro BAUER, Zoran RANKOVIC
  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
    Patent number: 10253041
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei Wu
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS
    Publication number: 20180118759
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Application
    Filed: July 21, 2016
    Publication date: May 3, 2018
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei WU
  • Oxazolo[5-4-b]pyridin-5-yl compounds
    Patent number: 8288548
    Abstract: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: October 16, 2012
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Raymond Gilmour, Jose Alfredo Martin, Eva Maria Martin de la Nava
  • OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS
    Publication number: 20120142724
    Abstract: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.
    Type: Application
    Filed: November 17, 2011
    Publication date: June 7, 2012
    Applicant: Eli Lilly and Company
    Inventors: David Andrew Coates, Raymond Gilmour, Jose Alfredo Martin, Eva Maria Martin de la Nava